About Cellicure, Inc.

Cellicure develops patented CAR-NK and CAR-T technologies that enhance the activation and persistence of natural killer and T cells for immunotherapy. The company addresses the unmet clinical needs of patients with solid tumors and hematological malignancies by providing effective cell-based treatments for cancer and chronic inflammatory diseases.

```xml <problem> Current cell-based cancer immunotherapies face challenges in effectively targeting and eradicating solid tumors and hematological malignancies due to limitations in cell activation, persistence, and scalability. Traditional methods of natural killer (NK) cell expansion and T-cell engineering often require continuous cytokine stimulation and lack the ability to overcome inhibitory signaling barriers, hindering their therapeutic potential. </problem> <solution> Cellicure develops and patents CAR-NK and CAR-T cell technologies designed to enhance the activation and persistence of immune cells for improved cancer immunotherapy. Their complete signaling CAR (csCAR-NK) technology overcomes inhibitory signaling in NK cells, leading to complete activation. The cytokine-free renewable NK (reNKTM) platform enables long-term NK cell renewability without continuous cytokine stimulation. Cellicure's NK expansion system (Effic-NKTM) simplifies the NK cell expansion process, increasing efficiency and reducing costs. The nCAR-TTM platform enhances the persistence of CAR-T cells, improving their immunotherapy efficacy. </solution> <features> - csCAR-NK: Complete signaling CAR technology that enhances NK cell activation by overcoming inhibitory signals. - reNKTM: Cytokine-free renewable NK cell platform enabling long-term NK cell expansion without continuous cytokine stimulation. - Effic-NKTM: NK cell expansion system that simplifies the expansion process, improving efficiency and reducing costs. - nCAR-TTM: CAR-T cell platform that enhances CAR-T cell persistence for improved immunotherapy efficacy. </features> <target_audience> Cellicure's primary target audience includes researchers and clinicians in the fields of oncology and immunology, as well as pharmaceutical companies developing cell-based immunotherapies for cancer and chronic inflammatory diseases. </target_audience> ```

What does Cellicure, Inc. do?

Where is Cellicure, Inc. located?

Cellicure, Inc. is based in Germantown, United States.

When was Cellicure, Inc. founded?

Cellicure, Inc. was founded in 2021.

How much funding has Cellicure, Inc. raised?

Cellicure, Inc. has raised 5400000.

Location

Germantown, United States

Founded

2021

Funding

5400000

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Cellicure, Inc.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

cellicure.com 100+

Founded 2021 – Germantown, United States

Funding

Estimated Funding

$5M+

Team

No team information available.

Company Description

Problem

Current cell-based cancer immunotherapies face challenges in effectively targeting and eradicating solid tumors and hematological malignancies due to limitations in cell activation, persistence, and scalability. Traditional methods of natural killer (NK) cell expansion and T-cell engineering often require continuous cytokine stimulation and lack the ability to overcome inhibitory signaling barriers, hindering their therapeutic potential.

Solution

Cellicure develops and patents CAR-NK and CAR-T cell technologies designed to enhance the activation and persistence of immune cells for improved cancer immunotherapy. Their complete signaling CAR (csCAR-NK) technology overcomes inhibitory signaling in NK cells, leading to complete activation. The cytokine-free renewable NK (reNKTM) platform enables long-term NK cell renewability without continuous cytokine stimulation. Cellicure's NK expansion system (Effic-NKTM) simplifies the NK cell expansion process, increasing efficiency and reducing costs. The nCAR-TTM platform enhances the persistence of CAR-T cells, improving their immunotherapy efficacy.

Features

csCAR-NK: Complete signaling CAR technology that enhances NK cell activation by overcoming inhibitory signals.

reNKTM: Cytokine-free renewable NK cell platform enabling long-term NK cell expansion without continuous cytokine stimulation.

Effic-NKTM: NK cell expansion system that simplifies the expansion process, improving efficiency and reducing costs.

nCAR-TTM: CAR-T cell platform that enhances CAR-T cell persistence for improved immunotherapy efficacy.

Target Audience

Cellicure's primary target audience includes researchers and clinicians in the fields of oncology and immunology, as well as pharmaceutical companies developing cell-based immunotherapies for cancer and chronic inflammatory diseases.